Registered title, quoted from ClinicalTrials.gov
A Clinical Study of of RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas
An open trial on lymphoma, registered on ClinicalTrials.gov. Led by Affiliated Hospital of Jiangsu University; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07316920, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 8
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (8 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Histologically confirmed large B-cell lymphoma, follicular lymphoma, mantle-cell lymphoma, or indolent lymphoma transformed to DLBCL; CD19 and/or CD20 positive.
Inclusion criterion 4
Large B-cell lymphoma, grade 3B follicular lymphoma, transformed indolent lymphoma: i. Primary refractory and ineligible/unable to receive autologous CAR-T: best response PD after ≥2 cycles of first-line therapy, or SD after ≥4 cycles.
Inclusion criterion 7
Grade 1, 2, or 3A follicular lymphoma: i. Primary refractory and ineligible/unable to receive autologous CAR-T: best response PD after ≥2 cycles of first-line therapy.
Inclusion criterion 8
Mantle-cell lymphoma: i. Primary refractory and ineligible/unable to receive autologous CAR-T: best response PD after ≥2 cycles of first-line therapy, or SD after ≥4 cycles.
Inclusion criterion 9
Toxicities from prior anti-cancer therapy (except alopecia, nausea, and the above lab values) must have stabilized at baseline or resolved to ≤Grade 1.
Inclusion criterion 19
Subjects of reproductive potential must use effective contraception for ≥12 months after completing study therapy.
Inclusion criterion 21
Malignancy that received curative therapy and has shown no evidence of active disease for ≥2 years before enrolment; or
Exclusion criterion 3
Major surgery within 2 weeks before screening or planned within 2 weeks after study treatment (local anaesthesia allowed).
Exclusion criterion 35
ECOG performance status 0-1.
Inclusion criterion 3
Hemoglobin ≥8.0 g/dL (no transfusion within 7 days).
Inclusion criterion 12
Platelets ≥50×10⁹/L (no transfusion within 7 days).
Inclusion criterion 13
ANC ≥1.0×10⁹/L (growth-factor support allowed if none within 7 days of test).
Inclusion criterion 14
AST/ALT ≤3×ULN (≤5×ULN if liver involvement).
Inclusion criterion 15
Serum creatinine ≤1.5×ULN or CrCl ≥60 mL/min (Cockcroft-Gault).
Inclusion criterion 16
Total bilirubin ≤2×ULN (≤3×ULN if liver involvement); except congenital bilirubin disorders (e.g., Gilbert's syndrome: direct bilirubin ≤1.5×ULN).
Inclusion criterion 17
INR, PT, APTT <1.5×ULN.
Inclusion criterion 18
At least one measurable lesion per Lugano criteria: nodal lesion longest diameter >1.5 cm, extranodal lesion >1.0 cm.
Inclusion criterion 5
Sum of the product of perpendicular diameters (SPD) of all measurable lesions ≥100 cm²;
Exclusion criterion 17
Positive screen for HBsAg, HBeAg, HBV DNA, HCV antibody, HCV RNA, or HIV antibody.
Exclusion criterion 36
WOCBP must have a negative high-sensitivity serum β-hCG pregnancy test at screening and again before the first dose of cyclophosphamide/fludarabine.
Inclusion criterion 20
Lactating women.
Exclusion criterion 38
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07316920, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Voluntary participation; full understanding of the study and provision of written informed consent obtained before any study-related procedure not part of standard care; willingness to comply with follow-up.
- Age 18-75 years; either sex.
- ECOG performance status 0-1.
- Histologically confirmed large B-cell lymphoma, follicular lymphoma, mantle-cell lymphoma, or indolent lymphoma transformed to DLBCL; CD19 and/or CD20 positive.
- At least one measurable lesion per Lugano criteria: nodal lesion longest diameter >1.5 cm, extranodal lesion >1.0 cm.
- Prior treatment response must meet one of the following:
- Large B-cell lymphoma, grade 3B follicular lymphoma, transformed indolent lymphoma: i. Primary refractory and ineligible/unable to receive autologous CAR-T: best response PD after ≥2 cycles of first-line therapy, or SD after ≥4 cycles.
ii. Relapse ≤12 months after achieving CR with first-line chemo-immunotherapy. iii. Relapse/progression ≤12 months after autologous HSCT. iv. Refractory to, relapsed after, or progressed on ≥2 prior lines (including autologous CAR-T): best response PD or SD after ≥2 cycles of the most recent regimen.
v. Transformed indolent lymphoma: prior chemotherapy for iNHL and ≥1 systemic regimen after transformation, fulfilling the above refractory/relapse criteria.
- Grade 1, 2, or 3A follicular lymphoma: i. Primary refractory and ineligible/unable to receive autologous CAR-T: best response PD after ≥2 cycles of first-line therapy.
ii. Refractory to, relapsed after, or progressed on ≥2 prior lines (including autologous CAR-T): best response PD or SD after ≥2 cycles of the most recent regimen.
- Mantle-cell lymphoma: i. Primary refractory and ineligible/unable to receive autologous CAR-T: best response PD after ≥2 cycles of first-line therapy, or SD after ≥4 cycles.
ii. Refractory to, relapsed after, or progressed on ≥2 prior lines (including autologous CAR-T): best response PD or SD after ≥2 cycles of the most recent regimen.
- Estimated life expectancy ≥3 months.
- Screening laboratory values (may be repeated once):
- Hemoglobin ≥8.0 g/dL (no transfusion within 7 days).
- Platelets ≥50×10⁹/L (no transfusion within 7 days).
- ANC ≥1.0×10⁹/L (growth-factor support allowed if none within 7 days of test).
- AST/ALT ≤3×ULN (≤5×ULN if liver involvement).
- Serum creatinine ≤1.5×ULN or CrCl ≥60 mL/min (Cockcroft-Gault).
- Total bilirubin ≤2×ULN (≤3×ULN if liver involvement); except congenital bilirubin disorders (e.g., Gilbert's syndrome: direct bilirubin ≤1.5×ULN).
- INR, PT, APTT <1.5×ULN.
- Toxicities from prior anti-cancer therapy (except alopecia, nausea, and the above lab values) must have stabilized at baseline or resolved to ≤Grade 1.
- WOCBP must have a negative high-sensitivity serum β-hCG pregnancy test at screening and again before the first dose of cyclophosphamide/fludarabine.
- Subjects of reproductive potential must use effective contraception for ≥12 months after completing study therapy.
Exclusion Criteria:
- Subjects with any of the following conditions are ineligible for this trial:
- Any malignancy other than B-cell non-Hodgkin lymphoma ever diagnosed or treated, except:
- Malignancy that received curative therapy and has shown no evidence of active disease for ≥2 years before enrolment; or
- Adequately treated non-melanoma skin cancer with no current evidence of disease.
- Prior anti-cancer therapy within the stated windows (before lymphodepletion):
- CNS prophylaxis (e.g., intrathecal methotrexate and/or cytarabine) within 7 days;
- Cytotoxic chemotherapy or radiotherapy within 14 days;
- Small-molecule targeted or epigenetic therapy within 14 days or 5 half-lives, whichever is longer;
- Monoclonal antibody, bispecific antibody, or antibody-drug conjugate within 21 days or 5 half-lives, whichever is shorter;
- Investigational drug or invasive investigational device within 28 days (if the therapy is also investigational, the 28-day wash-out applies);
- Autologous haematopoietic stem-cell transplant or CD19-directed autologous CAR-T therapy within 100 days.
- Any autologous cellular or gene therapy other than CD19-directed autologous CAR-T.
- Any allogeneic cellular (including CAR-T) or gene therapy.
- Prior allogeneic haematopoietic stem-cell transplantation.
- Positive donor-specific antibody (DSA).
- At least one of the following high-risk features:
- Sum of the product of perpendicular diameters (SPD) of all measurable lesions ≥100 cm²;
- Bulky disease: single mass ≥7.5 cm; mediastinal mass with maximum diameter >1/3 of thoracic diameter;
- Obstructive/compressive emergency (e.g., bowel obstruction, vascular compression) requiring urgent intervention at screening.
- Active CNS involvement (symptomatic or positive CSF/imaging); subjects with prior CNS disease now in remission (asymptomatic with negative CSF and imaging) are eligible.
- Significant bleeding diathesis: gastrointestinal bleeding, haemorrhagic cystitis, coagulopathy, hypersplenism (splenomegaly on exam/US, cytopenias, hyperplastic marrow) or ongoing anticoagulation.
- Chronic concomitant systemic corticosteroids or other immunosuppressants, except: topical, ocular, intra-articular, nasal or inhaled corticosteroids; short-course steroids for prophylaxis (e.g., contrast allergy).
- Severe underlying medical conditions:
- Active serious viral, bacterial or uncontrolled systemic fungal infection;
- Active systemic autoimmune disease requiring therapy.
- Significant cardiac disease:
- NYHA class III or IV congestive heart failure;
- Myocardial infarction or CABG within 6 months before enrolment;
- Clinically relevant ventricular arrhythmia or unexplained syncope not vasovagal or dehydration-related;
- Severe non-ischaemic cardiomyopathy;
- Left ventricular ejection fraction (LVEF) <45% by echo or MUGA within 4 weeks before lymphodepletion.
- Resting oxygen saturation <92%.
- Clinically relevant prior or current CNS disorder: epilepsy, seizure-like episodes, paralysis, aphasia, stroke, severe head trauma, dementia, Parkinson's disease, cerebellar disorder, organic brain syndrome or major psychiatric illness.
- Live-attenuated vaccine within 4 weeks before screening.
- Major surgery within 2 weeks before screening or planned within 2 weeks after study treatment (local anaesthesia allowed).
- Positive screen for HBsAg, HBeAg, HBV DNA, HCV antibody, HCV RNA, or HIV antibody.
- Life-threatening allergy, hypersensitivity or intolerance to study-drug excipients including, but not limited to, DMSO.
- Lactating women.
- Any condition that, in the investigator's opinion, renders the subject unsuitable for the study.
Quoted from ClinicalTrials.gov, NCT07316920, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07316920, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.